Giuseppe Viale
YOU?
Author Swipe
View article: Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00
Role of immunosuppressive JNK pathway in the tumor microenvironment among TNBC subtypes in IBCSG trial 22-00 Open
Phosphorylation of the JNK (pJNK) protein promotes an immunosuppressive tumor microenvironment (TME), enhancing aggressiveness in inflammatory triple-negative breast cancer (TNBC). This study evaluated the role of JNK signaling using a gen…
View article: Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06
Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06 Open
For patients with HER2 IHC 0 mBC, rescoring and/or retesting with the Roche HER2 4B5 assay is encouraged to determine eligibility for T-DXd.
View article: 124P Risk stratification in HR+/HER2- EBC: A comparative study of Prosigna and Oncotype DX with emphasis on menopausal status and lymph node involvement
124P Risk stratification in HR+/HER2- EBC: A comparative study of Prosigna and Oncotype DX with emphasis on menopausal status and lymph node involvement Open
View article: Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial
Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial Open
View article: Sex hormones, the anticancer immune response, and therapeutic opportunities
Sex hormones, the anticancer immune response, and therapeutic opportunities Open
View article: Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates
Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates Open
Background The surrogacy of overall response rate (ORR) or progression-free survival (PFS) for overall survival (OS) at the trial-level in randomized clinical trials (RCTs) testing antibody-drugs conjugates (ADC) has never been investigate…
View article: Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Publisher Correction: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial Open
View article: Data from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Data from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Purpose:We assessed the 27-gene RT-qPCR–based DetermaIO assay and the same score calculated from RNA sequencing (RNA-seq) data as predictors of sensitivity to immune checkpoint therapy in the neoTRIPaPDL1 randomized trial that compared neo…
View article: Supplementary Data S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Data S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Data S1. FPKM RNA-Seq data for the genes included in the IO score signature.
View article: Supplementary Table S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Table 4. Univariate regression of pCR according to TNBC subtypes in the RNA-Seq cohort. One-vs-all approach was applied.
View article: Supplementary Figure S7 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure S7 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Figure 7. Association of TNBC subtypes and IO classifications. A) Frequency of RT-qPCR DetermaIO class by TNBC subtype; B) Frequency of RNAseq IO classes by TNBC subtype. C) Multivariable logistic regression model with TNBC s…
View article: Supplementary Figure S6 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure S6 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Figure 6. Comparison of TNBC subtype classification systems. A) Sankey plot showing the overlap between the TNBC subtype classification according to Ring and colleagues and the original TNBCtypes from Lehmann and colleagues B…
View article: Supplementary Figure S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure S4 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Figure 4. Baseline RNA-Seq IO score. A) Frequency of IO+ and IO− patients in the overall NeoTRIP population (left) and by treatment arm (right); B) Association between IO classes and PD-L1 status (left) or sTILs (right); C) p…
View article: Supplementary Figure S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Figure 1. Quality control of NeoTRIP RNA-Seq data. Boxplots showing the distribution of read depth of targeted coding regions by arm and response status. Dots represent the read depth of single samples. The horizontal grey da…
View article: Supplementary Figure S2 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure S2 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Figure 2. Comparison of RT-qPCR DetermaIO and RNA-Seq IO scores. A) Scatter plot showing the relation between continuous IO scores. Concordance and correlation coefficient = 0.94; 95% CI = 0.92 − 0.95; B) Contingency plot of …
View article: Supplementary Table S3 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table S3 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Table 3. Univariate and multivariable regression of pCR according to NGS-based IO score in the RNA-Seq cohort.
View article: Supplementary Figure S3 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure S3 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Figure 3. Continuous baseline RT-qPCR DetermaIO score. Distribution of continuous IO score by treatment arm and pCR status. P-values by logistic regression.
View article: Supplementary Figure S5 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Figure S5 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Figure 5. Comparison of IO score with additional immune signatures. A) Correlation of RT-qPCR and RNA-Seq continuous IO score in the respective NeoTRIP cohorts with previously published immune signatures; B) Comparison of uni…
View article: Supplementary Table S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table S1 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Table 1. List of 27 genes of the DetermaIO assay.
View article: Supplementary Table S5 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table S5 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Table 5. Multivariable regression of pCR according to NGS-based IO score and TNBC subtypes in the RNA-Seq cohort. For TNBC subtypes LAR was taken as reference group.
View article: Supplementary Table S2 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
Supplementary Table S2 from The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Supplementary Table 2. Patients’ characteristics of the NeoTRIP trial in the RNA-Seq and RT-qPCR cohorts.
View article: Development and validation of a gene expression-based Breast Cancer Purity Score
Development and validation of a gene expression-based Breast Cancer Purity Score Open
The prevalence of malignant cells in clinical specimens, or tumour purity, is affected by both intrinsic biological factors and extrinsic sampling bias. Molecular characterization of large clinical cohorts is typically performed on bulk sa…
View article: The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer Open
Purpose: We assessed the 27-gene RT-qPCR–based DetermaIO assay and the same score calculated from RNA sequencing (RNA-seq) data as predictors of sensitivity to immune checkpoint therapy in the neoTRIPaPDL1 randomized trial that compared ne…
View article: Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial Open
View article: Global Study on the Accuracy of Human Epidermal Growth Factor Receptor 2-Low Diagnosis in Breast Cancer
Global Study on the Accuracy of Human Epidermal Growth Factor Receptor 2-Low Diagnosis in Breast Cancer Open
Context.— Recently, a new type of antibody-drug conjugate, trastuzumab-deruxtecan (T-DXd), has been approved for the treatment of metastatic breast cancer with low level of human epidermal growth factor receptor 2 (HER2) gene expression. T…
View article: Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT Open
PURPOSE Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)–positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet need…
View article: Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis
Outcomes of patients with advanced solid tumors who discontinued immune-checkpoint inhibitors: a systematic review and meta-analysis Open
View article: 109O Adjuvant endocrine therapy for premenopausal invasive lobular carcinoma (ILC): Results from SOFT and TEXT phase III studies
109O Adjuvant endocrine therapy for premenopausal invasive lobular carcinoma (ILC): Results from SOFT and TEXT phase III studies Open
Data from BIG1-98 along with pre-clinical findings point to a partial resistance to tamoxifen (T) among postmenopausal women diagnosed with ILC. The TEXT and SOFT trials assigned premenopausal women with hormone receptor-positive (ER+) tum…
View article: Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ
Expression of immune-related genes and breast cancer recurrence in women with ductal carcinoma in situ Open
View article: Development and validation of a gene expression score to account for tumour purity and improve prognostication in breast cancer
Development and validation of a gene expression score to account for tumour purity and improve prognostication in breast cancer Open
The prevalence of malignant cells in clinical specimens, or tumour purity, is affected by both intrinsic biological factors and extrinsic sampling bias. Molecular characterization of large clinical cohorts is typically performed on bulk sa…